

## Correction

**Correction: The *PTPN22* 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden**Heidi Kokkonen<sup>1</sup>, Martin Johansson<sup>1</sup>, Lena Innala<sup>1</sup>, Erik Jidell<sup>2</sup> and Solbritt Rantapää-Dahlqvist<sup>1</sup><sup>1</sup>Department of Rheumatology, University Hospital, SE-901 85 Umeå, Sweden<sup>2</sup>Department of Transfusion Medicine, University Hospital, SE-901 85 Umeå, SwedenCorresponding author: Solbritt Rantapää-Dahlqvist, [solbritt.rantapaa.dahlqvist@medicin.umu.se](mailto:solbritt.rantapaa.dahlqvist@medicin.umu.se)

Published: 25 October 2007

This article is online at <http://arthritis-research.com/content/9/5/403>

© 2007 BioMed Central Ltd

*Arthritis Research & Therapy* 2007, **9**:403 (doi:10.1186/ar2312)See related research article by Kokkonen *et al.*, <http://arthritis-research.com/content/9/3/R56>

After publication of our recent article [1], we noticed an error in Table 6 'Relative risk for developing rheumatoid arthritis in patients, stratified for anti-cyclic citrullinated peptide (anti-CCP) antibodies'.

Under the heading of 'Anti-CCP antibody-positive', the first line should read 'HLA-shared epitope-negative', and the second line should read 'HLA-shared epitope-positive'. Similarly, under the heading 'Anti-CCP antibody-negative', the first line should read 'HLA-shared epitope-negative' and the second line should read 'HLA-shared epitope-positive'.

The correct table is given here as Table 1 (a corrected version of Table 6 [1]).

**Reference**

1. Kokkonen H, Johansson M, Innala L, Jidell E, Rantapää-Dahlqvist S: **The *PTPN22* 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden.** *Arthritis Res Ther* 2007, **9**:R56.

**Table 1****Relative risk for developing rheumatoid arthritis in patients, stratified for anti-cyclic citrullinated peptide (anti-CCP) antibodies**

	Nonsmoking		Smoking	
	Cases/controls	Relative risk (95% confidence interval)	Cases/controls	Relative risk confidence interval)
Anti-CCP antibody-positive				
HLA-shared epitope-negative	33/41	1.00	71/49	1.67 (0.95-2.94)
HLA-shared epitope-positive	62/33	2.05 (1.12-3.75)	143/21	7.61 (4.05-14.30)
Anti-CCP antibody-negative				
HLA-shared epitope-negative	40/41	1.00	52/49	1.11 (0.63-1.95)
HLA-shared epitope-positive	23/33	0.71 (0.37-1.38)	31/21	1.92 (0.98-3.77)

The combination of carriage of HLA-shared epitope alleles or not, and ever or never smoking were compared for groups stratified for anti-CCP antibodies.